(DCI) Donaldson - Overview
Stock: Filters, Collectors, Purifiers, Bioprocessing, Membranes
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.55% |
| Yield on Cost 5y | 2.55% |
| Yield CAGR 5y | 7.69% |
| Payout Consistency | 99.5% |
| Payout Ratio | 31.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.2% |
| Relative Tail Risk | -6.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.76 |
| Alpha | 44.04 |
| Character TTM | |
|---|---|
| Beta | 0.842 |
| Beta Downside | 0.791 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.81% |
| CAGR/Max DD | 0.92 |
Description: DCI Donaldson January 06, 2026
Donaldson Company Inc. (NYSE: DCI) designs, manufactures, and distributes filtration systems and replacement parts across three operating segments: Mobile Solutions, Industrial Solutions, and Life Sciences. The Mobile Solutions segment supplies air- and liquid-filtration components-such as fuel, lube, hydraulic, and emissions filters-to OEMs in construction, mining, agriculture, and transportation, as well as to independent distributors and dealer networks. The Industrial Solutions segment covers dust, fume, and mist collectors; compressed-air and gas-purification units; power-generation inlet systems; and aerospace/defense filtration for aircraft, ground-vehicle, and naval platforms. The Life Sciences segment provides micro-environment gas and liquid filtration for food-beverage, bioprocessing (bioreactors, fermenters, chromatography consumables), and high-purity applications in semiconductors, hard-disk drives, battery systems, and powertrain components.
Key performance indicators from the most recent fiscal year (2023) show total revenue of roughly $2.5 billion, an operating margin of ≈ 12 %, and a backlog of about $1.1 billion, indicating solid demand visibility. The company’s growth is tied to macro-drivers such as the global shift toward electric vehicles (which raises demand for high-efficiency coolant and battery filtration), expanding renewable-energy generation (requiring robust air-inlet and gas-purification for turbines), and continued expansion of biopharma manufacturing capacity, which fuels the Life Sciences segment.
Analysts should watch the OEM cycle in the construction and mining sectors-where a slowdown could compress Mobile Solutions sales-and monitor the pace of EV adoption, as higher-volume battery packs increase the need for specialized filtration. Additionally, the aerospace-defense market’s fiscal-year spending trends can materially affect the Industrial Solutions segment’s top line. For a deeper dive into DCI’s valuation metrics, the ValueRay platform offers a concise, data-rich overview.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 381.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 2.15 > 1.0 |
| NWC/Revenue: 21.75% < 20% (prev 18.65%; Δ 3.10% < -1%) |
| CFO/TA 0.16 > 3% & CFO 471.3m > Net Income 381.9m |
| Net Debt (463.3m) to EBITDA (633.3m): 0.73 < 3 |
| Current Ratio: 2.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (117.8m) vs 12m ago -3.36% < -2% |
| Gross Margin: 34.76% > 18% (prev 0.35%; Δ 3441 % > 0.5%) |
| Asset Turnover: 122.8% > 50% (prev 119.6%; Δ 3.17% > 0%) |
| Interest Coverage Ratio: 20.74 > 6 (EBITDA TTM 633.3m / Interest Expense TTM 25.8m) |
Altman Z'' 8.18
| A: 0.27 (Total Current Assets 1.51b - Total Current Liabilities 703.9m) / Total Assets 3.03b |
| B: 0.90 (Retained Earnings 2.72b / Total Assets 3.03b) |
| C: 0.18 (EBIT TTM 535.0m / Avg Total Assets 3.04b) |
| D: 2.19 (Book Value of Equity 3.31b / Total Liabilities 1.51b) |
| Altman-Z'' Score: 8.18 = AAA |
Beneish M -3.04
| DSRI: 1.01 (Receivables 655.6m/631.3m, Revenue 3.73b/3.64b) |
| GMI: 1.02 (GM 34.76% / 35.31%) |
| AQI: 0.96 (AQ_t 0.29 / AQ_t-1 0.30) |
| SGI: 1.02 (Revenue 3.73b / 3.64b) |
| TATA: -0.03 (NI 381.9m - CFO 471.3m) / TA 3.03b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of DCI shares?
Over the past week, the price has changed by +6.96%, over one month by +18.31%, over three months by +27.30% and over the past year by +56.68%.
Is DCI a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the DCI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 99.8 | -8.5% |
| Analysts Target Price | 99.8 | -8.5% |
| ValueRay Target Price | 137.9 | 26.5% |
DCI Fundamental Data Overview February 07, 2026
P/E Forward = 26.5957
P/S = 3.3893
P/B = 8.1419
P/EG = 2.4071
Revenue TTM = 3.73b USD
EBIT TTM = 535.0m USD
EBITDA TTM = 633.3m USD
Long Term Debt = 671.5m USD (from longTermDebt, last quarter)
Short Term Debt = 2.50m USD (from shortTermDebt, last quarter)
Debt = 674.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 463.3m USD (from netDebt column, last quarter)
Enterprise Value = 13.09b USD (12.63b + Debt 674.0m - CCE 210.7m)
Interest Coverage Ratio = 20.74 (Ebit TTM 535.0m / Interest Expense TTM 25.8m)
EV/FCF = 32.47x (Enterprise Value 13.09b / FCF TTM 403.2m)
FCF Yield = 3.08% (FCF TTM 403.2m / Enterprise Value 13.09b)
FCF Margin = 10.82% (FCF TTM 403.2m / Revenue TTM 3.73b)
Net Margin = 10.25% (Net Income TTM 381.9m / Revenue TTM 3.73b)
Gross Margin = 34.76% ((Revenue TTM 3.73b - Cost of Revenue TTM 2.43b) / Revenue TTM)
Gross Margin QoQ = 35.15% (prev 34.55%)
Tobins Q-Ratio = 4.33 (Enterprise Value 13.09b / Total Assets 3.03b)
Interest Expense / Debt = 1.05% (Interest Expense 7.10m / Debt 674.0m)
Taxrate = 22.78% (33.6m / 147.5m)
NOPAT = 413.1m (EBIT 535.0m * (1 - 22.78%))
Current Ratio = 2.15 (Total Current Assets 1.51b / Total Current Liabilities 703.9m)
Debt / Equity = 0.44 (Debt 674.0m / totalStockholderEquity, last quarter 1.52b)
Debt / EBITDA = 0.73 (Net Debt 463.3m / EBITDA 633.3m)
Debt / FCF = 1.15 (Net Debt 463.3m / FCF TTM 403.2m)
Total Stockholder Equity = 1.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.58% (Net Income 381.9m / Total Assets 3.03b)
RoE = 25.55% (Net Income TTM 381.9m / Total Stockholder Equity 1.49b)
RoCE = 24.70% (EBIT 535.0m / Capital Employed (Equity 1.49b + L.T.Debt 671.5m))
RoIC = 19.15% (NOPAT 413.1m / Invested Capital 2.16b)
WACC = 8.60% (E(12.63b)/V(13.30b) * Re(9.02%) + D(674.0m)/V(13.30b) * Rd(1.05%) * (1-Tc(0.23)))
Discount Rate = 9.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.98%
[DCF Debug] Terminal Value 79.27% ; FCFF base≈377.9m ; Y1≈464.5m ; Y5≈784.2m
Fair Price DCF = 98.40 (EV 11.81b - Net Debt 463.3m = Equity 11.35b / Shares 115.3m; r=8.60% [WACC]; 5y FCF grow 24.50% → 2.90% )
EPS Correlation: -10.14 | EPS CAGR: -44.62% | SUE: -4.0 | # QB: 0
Revenue Correlation: 79.58 | Revenue CAGR: 4.17% | SUE: 0.64 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.05 | Chg30d=-0.004 | Revisions Net=+4 | Analysts=7
EPS current Year (2026-07-31): EPS=4.05 | Chg30d=+0.006 | Revisions Net=+2 | Growth EPS=+10.0% | Growth Revenue=+3.7%
EPS next Year (2027-07-31): EPS=4.45 | Chg30d=+0.025 | Revisions Net=+2 | Growth EPS=+9.8% | Growth Revenue=+5.0%